RxDoctor Payments Data

Vikram Katari, MD

Clinical Cardiac Electrophysiology · Tulsa, OKNPI 1902946130

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $21,794 of the $33,695 with a category attached, or 64.7%. 11 manufacturers reported payments, led by Abbott at 51.1% of the total. 2025 is the largest year on record at $14,684, 7.7 times the $1,900 reported in 2019.

$33,695in general payments, 2019–2025

Across 353 payments — averaging $95.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$17K
  • Medical Device Business Services, Inc.$7K
  • Medtronic$5K
  • Biosense Webster, Inc.$3K
  • Boston Scientific$897
  • Atricure, Inc.$157
  • plus $370 from 5 others

What the payments were for

  • Travel & lodging$21,79465%
  • Food & beverage$10,26130%
  • Education$1,6405%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,695 in reported general payments places this provider in the 75th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.

See all clinical cardiac electrophysiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$368,772
Medicare patients
1,480
Services billed
5,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban851$854,762
XareltoRivaroxaban273$264,195
Metoprolol Succinate475$8,387
Dofetilide24$7,301
Flecainide Acetate114$4,525
Propafenone Hcl ErPropafenone Hcl12$4,171
Digoxin170$3,847
Diltiazem 24hr Er (Cd)Diltiazem Hcl136$2,729
SotalolSotalol Hcl101$2,617
Amiodarone Hcl167$2,516
Metoprolol Tartrate239$1,905
Carvedilol121$1,843
Atorvastatin Calcium80$1,640
Mexiletine Hcl22$1,621
Potassium Chloride83$1,613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$854,762851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.

Other clinical cardiac electrophysiology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →